✦ LIBER ✦

Phase II study of 4′-iodo-4′-deoxydoxorubicin in non-resectable non-small-cell lung cancer

Book ID: 122627935
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 297 KB
Volume: 10
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(94)90851-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of 4′-iodo-4′-deoxydoxoru

✍ Jens Benn Sørensen; Lars Stenbygaard; Lars Drivsholm; Per Dombernowsky; Heine H. 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 401 KB

Phase II study of 4′-iodo-4′-deoxydoxoru

Phase II study of 4′-iodo-4′-deoxydoxorubicin in patients with advanced, measurable non-small cell lung cancer

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Phase II studies of 4′-iodo-4′-deoxydoxo

Phase II studies of 4′-iodo-4′-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 157 KB

Phase II trial of 4′-deoxydoxorubicin (D

Phase II trial of 4′-deoxydoxorubicin (DxDx) in non-small cell lung cancer: A cancer and leukemia group B trial

✍ Ringenberg, Q. Scott ;Perry, Michael C. ;Propert, Kathleen J. ;Modeas, Caron ;Hi 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Phase II trial of esorubicin (4′deoxydox

Phase II trial of esorubicin (4′deoxydoxorubicin, DxDx) in patients with small cell lung cancer

✍ James R. Rigas; Mark G. Kris; Richard J. Gralla; Robert T. Heelan; Linda D. Mark 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 264 KB

Esorubicin (4'-deoxydoxorubicin or DxDx) is an analog of doxorubicin with preclinical antitumor activity and no significant cardiotoxicity in model systems. Eleven patients with small cell lung cancer who had previously received chemotherapy were given esorubicin (25 mg/m 2 intravenously) every 3 we

Phase II trial of 4′ deoxydoxorubicin (D

Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma

✍ Christopher Rose; Thomas E. Lad; Lary J. Kilton; Joel Schor; Steven T. Rosen; Ar 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 162 KB

A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four response